Findings

What do systematic reviews say?

5 questions · 5 findings · 1 reviews

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 2 · 40%Low 3 · 60%Moderate 0 · 0%High 0 · 0%

Adherence: Discontinuations · people with transfusion‐dependent thalassemia

Deferasirox showed no clear difference in adherence: discontinuations compared with deferiprone (low certainty).

1 finding from 1 review

Deferasirox for managing iron overload in people with thalassaemia 2017 · Cochrane Headline outcomes only
RR 0.16 [0.01, 2.99]
3 studies · 179 participants
Low

Adherence: Discontinuations · people with non‐transfusion‐dependent thalassemia

Deferasirox showed no clear difference in adherence: Discontinuations compared with placebo (low certainty).

1 finding from 1 review

Deferasirox for managing iron overload in people with thalassaemia 2017 · Cochrane Headline outcomes only
RR 1.32 [0.5, 3.52]
1 study · 166 participants
Low

Adherence: Discontinuations · people with transfusion‐dependent thalassemia

Deferasirox showed no clear difference in adherence: discontinuations compared with deferoxamine (low certainty).

1 finding from 1 review

Deferasirox for managing iron overload in people with thalassaemia 2017 · Cochrane Headline outcomes only
RR 0.95 [0.6, 1.5]
8 studies · 1211 participants
Low

Adherence: Discontinuations · people with transfusion‐dependent thalassemia

1 finding from 1 review

Deferasirox for managing iron overload in people with thalassaemia 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 96 participants
Very low

Adherence: Discontinuations · people with transfusion‐dependent thalassemia

1 finding from 1 review

Deferasirox for managing iron overload in people with thalassaemia 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 94 participants
Very low